| Aug 12 |
ORIC Pharmaceuticals GAAP EPS of -$0.45
|
| Aug 12 |
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
|
| Jul 29 |
ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation
|
| Jul 17 |
ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
|
| Jul 17 |
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
|
| Jul 16 |
ORIC collaborates with Bayer, J&J on prostate cancer study
|
| Jul 16 |
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
|
| Jul 9 |
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
|
| Jul 8 |
Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?
|
| Jun 7 |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
